LAB Valuation

Standard BioTools Inc

Add to Watchlist

Advanced Chart

1.360

+0.1(7.937%)1D

Overview
Forecast
Valuation
Earnings

LAB Relative Valuation

LAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LAB is overvalued; if below, it's undervalued.

Historical Valuation

Standard BioTools Inc (LAB) is now in the Fair zone, suggesting that its current forward PS ratio of 2.72 is considered Fairly compared with the five-year average of -12.61. The fair price of Standard BioTools Inc (LAB) is between 0.82 to 1.73 according to relative valuation methord.

Relative Value

Fair Zone

0.82-1.73

Current Price：1.36

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.05

P/B

Median3y

-0.45

Median5y

1.31

-26.52

FCF Yield

Median3y

-36.57

Median5y

-27.82

Competitors Valuation Multiple

The average P/S ratio for LAB's competitors is 2.23, providing a benchmark for relative valuation. Standard BioTools Inc Corp (LAB) exhibits a P/S ratio of 2.72, which is 21.98% above the industry average. Given its robust revenue growth of -10.42%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LAB.O

Standard BioTools Inc

2.72

Average P/S: 2.23

-10.42%